Affinity Asset Advisors, LLC
Affinity Asset Advisors, LLC reported 101 US-listed holdings worth $2.02 billion in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: Roivant Sciences Ltd. (6.6%), Apogee Therapeutics Inc. (6.5%) and Spyre Therapeutics Inc. (5.6%). Against the quarter before, it opened 18 positions, added to 32, trimmed 28 and sold out of 9.
Reported holdings$2.02B+20.3% on Q1 2026
Positions101+9 on Q1 2026
The largest ten43.2%of its reported holdings
Latest 13FQ2 2026filed 13 August 2026
Added toHeldTrimmed
The 14 largest of its 101 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Opened 18Added 32Held 23Trimmed 28Sold out 9
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 18
- First Tracks Biotherapeutics TRAX$40.9 million
- Ideaya Biosciences Inc. IDYA$14.9 million
- Odyssey Therapeutics, Inc. ODTX$14.3 million
- Uniqure NV QURE$8.1 million
- Ascendis Pharma A/s ASND$8.0 million
- Assembly Biosciences Inc. ASMB$5.2 million
- Hemab Therapeutics Hldgs Inc. COAG$5.1 million
- Research Alliance Corp Iii Ord Shs Cl A RACC$4.0 million
and 10 more in the table below
Added to 32
- Roivant Sciences Ltd. ROIV+950,000 shares · +34%
- Avalo Therapeutics Inc. AVTX+1.6 million shares · +116%
- Revolution Medicines, Inc. RVMD+150,000 shares · +150%
- Insmed Inc. INSM+170,000 shares · +35%
- Belite Bio Inc. BLTE+100,000 shares · +154%
- Sagimet Biosciences Inc. SGMT+1.6 million shares · +188%
- Relay Therapeutics Inc. RLAY+650,000 shares · +162%
- Alto Neuroscience Inc. ANRO+350,000 shares · +70%
and 24 more in the table below
Trimmed 28
- Apogee Therapeutics Inc. APGE-297,926 shares · -23%
- Teva Pharmaceutical Industries Ltd. TEVA-1.0 million shares · -73%
- Cytokinetics Inc. CYTK-150,483 shares · -21%
- Alkermes plc. ALKS-225,000 shares · -17%
- Cogent Biosciences Inc. COGT-300,000 shares · -40%
- Compass Pathways PLC CMPS-807,300 shares · -73%
- Abivax SA ABVX-75,000 shares · -19%
- Madrigal Pharmaceuticals Inc. MDGL-15,000 shares · -27%
and 20 more in the table below
Sold out of 9
- Centessa Pharmaceuticals PLC CNTA$55.6 million last quarter
- Arcellx Inc. ACLX$41.7 million last quarter
- Terns Pharmaceuticals Inc. TERN$29.7 million last quarter
- Ascendis Pharma A/s ASND$21.7 million last quarter
- Bridgebio Pharma Inc. BBIO$11.1 million last quarter
- Wave Life Sciences Ltd WVE$10.2 million last quarter
- Engene Holdings Inc. ENGN$4.2 million last quarter
- Corcept Therapeutics Inc. CORT$2.0 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Roivant Sciences Ltd. ROIV | 3,750,000 | $132.7 million | 6.58% | +950,000 |
| Apogee Therapeutics Inc. APGE | 987,000 | $131.0 million | 6.50% | -297,926 |
| Spyre Therapeutics Inc. SYRE | 1,279,134 | $113.6 million | 5.63% | no change |
| Xenon Pharmaceuticals Inc. XENE | 1,595,000 | $96.3 million | 4.77% | -80,000 |
| Erasca Inc. ERAS | 5,250,000 | $96.2 million | 4.77% | -100,000 |
| Insmed Inc. INSM | 650,000 | $69.3 million | 3.44% | +170,000 |
| Praxis Precision Medicines I PRAX | 185,000 | $61.9 million | 3.07% | +15,000 |
| Alkermes plc. ALKS | 1,125,000 | $58.9 million | 2.92% | -225,000 |
| Oruka Therapeutics Inc. ORKA | 590,000 | $56.2 million | 2.78% | +90,327 |
| Anaptysbio Inc. ANAB | 826,109 | $55.8 million | 2.77% | -113,891 |
| Avalo Therapeutics Inc. AVTX | 2,900,000 | $53.6 million | 2.66% | +1,559,160 |
| Cytokinetics Inc. CYTK | 550,000 | $46.9 million | 2.32% | -150,483 |
| Revolution Medicines, Inc. RVMD | 250,000 | $46.8 million | 2.32% | +150,000 |
| Abivax SA ABVX | 330,000 | $44.0 million | 2.18% | -75,000 |
| First Tracks Biotherapeutics TRAX | 2,032,012 | $40.9 million | 2.03% | new |
| Dianthus Therapeutics Inc. DNTH | 400,000 | $39.0 million | 1.93% | +50,000 |
| Sutro Biopharma Inc. STRO | 1,172,487 | $38.9 million | 1.93% | +102,968 |
| Nuvalent Inc. NUVL | 275,000 | $34.0 million | 1.68% | -25,000 |
| Trevi Therapeutics Inc. TRVI | 1,800,172 | $33.6 million | 1.66% | -200,000 |
| Ovid Therapeutics Inc. OVID | 10,144,562 | $27.3 million | 1.35% | -491,756 |
| Lexeo Therapeutics Inc. LXEO | 5,807,611 | $27.0 million | 1.34% | +757,400 |
| Celldex Therapeutics Inc. CLDX | 700,000 | $26.0 million | 1.29% | +200,000 |
| Belite Bio Inc. BLTE | 165,000 | $25.4 million | 1.26% | +100,000 |
| Enliven Therapeutics Inc. ELVN | 500,000 | $25.4 million | 1.26% | -86,904 |
| Forte Biosciences Inc. FBRX | 1,145,391 | $24.3 million | 1.21% | +133,501 |
| Nurix Therapeutics Inc. NRIX | 967,620 | $23.5 million | 1.16% | no change |
| Alto Neuroscience Inc. ANRO | 850,000 | $22.4 million | 1.11% | +350,000 |
| Madrigal Pharmaceuticals Inc. MDGL | 40,000 | $21.5 million | 1.07% | -15,000 |
| Protagonist Therapeutics, Inc. PTGX | 172,125 | $21.1 million | 1.05% | no change |
| Mineralys Therapeutics Inc. MLYS | 750,000 | $20.2 million | 1.00% | no change |
| Relay Therapeutics Inc. RLAY | 1,050,000 | $19.6 million | 0.97% | +650,000 |
| Sagimet Biosciences Inc. SGMT | 2,497,864 | $19.3 million | 0.96% | +1,629,844 |
| Jade Biosciences Inc. JBIO | 840,350 | $18.7 million | 0.93% | +200,394 |
| Cogent Biosciences Inc. COGT | 450,000 | $17.4 million | 0.86% | -300,000 |
| Travere Therapeutics Inc. TVTX | 300,000 | $17.0 million | 0.85% | no change |
| Cullinan Therapeutics Inc. CGEM | 875,760 | $15.9 million | 0.79% | +94,500 |
| Savara Inc. SVRA | 2,512,153 | $15.5 million | 0.77% | no change |
| Ideaya Biosciences Inc. IDYA | 400,000 | $14.9 million | 0.74% | new |
| Perspective Therapeutics Inc CATX | 4,214,582 | $14.4 million | 0.71% | +1,050,000 |
| Odyssey Therapeutics, Inc. ODTX | 766,346 | $14.3 million | 0.71% | new |
| Helix Acquisition Corp. III HLXC | 1,250,000 | $13.3 million | 0.66% | no change |
| Equillium Inc. EQ | 4,100,000 | $13.1 million | 0.65% | +2,873,690 |
| Establishment Labs Holdings In ESTA | 148,013 | $12.7 million | 0.63% | +48,013 |
| Eliem Therapeutics Inc. CLYM | 972,000 | $12.7 million | 0.63% | +272,000 |
| Teva Pharmaceutical Industries Ltd. TEVA | 374,000 | $12.7 million | 0.63% | -1,026,000 |
| Veradermics Inc MANE | 100,000 | $12.3 million | 0.61% | +30,000 |
| Arrowhead Pharmaceuticals, Inc. ARWR | 150,000 | $12.2 million | 0.61% | -50,000 |
| Taysha Gene Therapies Inc. TSHA | 1,750,000 | $11.9 million | 0.59% | +750,000 |
| Galecto Inc. DMRA | 425,000 | $11.1 million | 0.55% | -25,000 |
| Eupraxia Pharmaceuticals Inc. EPRX | 1,650,000 | $10.9 million | 0.54% | +60,995 |
| Vera Therapeutics Inc. VERA | 250,000 | $10.7 million | 0.53% | no change |
| Proqr Thrapeutics N V PRQR | 5,543,936 | $10.3 million | 0.51% | +3,089,658 |
| Newamsterdam Pharma Company NAMS | 275,000 | $9.3 million | 0.46% | no change |
| Korro Bio Inc. KRRO | 706,904 | $9.3 million | 0.46% | no change |
| Anteris Technologies Global AVR | 912,397 | $9.0 million | 0.45% | no change |
| Zura Bio Ltd ZURA | 1,464,303 | $8.6 million | 0.43% | -1,100,000 |
| Uniqure NV QURE | 175,000 | $8.1 million | 0.40% | new |
| Ascendis Pharma A/s ASND | 30,000 | $8.0 million | 0.40% | new |
| Ibio Inc. Com IBIO | 4,007,881 | $7.0 million | 0.35% | +900,681 |
| Generate Biomedicines Inc. GENB | 400,000 | $6.7 million | 0.33% | +50,000 |
| Tyra Biosciences Inc. TYRA | 200,012 | $6.4 million | 0.32% | -57,500 |
| Sol Gel Technologies SLGL | 84,900 | $6.3 million | 0.31% | +49,900 |
| Sab Biotherapeutics Inc. SABS | 1,525,000 | $5.9 million | 0.29% | +950,000 |
| Macrogenics Inc. MGNX | 1,216,606 | $5.6 million | 0.28% | +716,606 |
| Crispr Therapeutics AG CRSP | 100,000 | $5.5 million | 0.27% | -50,000 |
| Newamsterdam Pharma Company | 245,000 | $5.3 million | 0.26% | no change |
| Assembly Biosciences Inc. ASMB | 190,000 | $5.2 million | 0.26% | new |
| Rezolute Inc. RZLT | 1,000,000 | $5.2 million | 0.26% | -547,641 |
| Precision Biosciences Inc. DTIL | 646,576 | $5.1 million | 0.25% | +48,630 |
| Hemab Therapeutics Hldgs Inc. COAG | 138,030 | $5.1 million | 0.25% | new |
| Viridian Therapeutics Inc. VRDN | 250,000 | $4.6 million | 0.23% | no change |
| Arrivent Biopharma Inc. AVBP | 125,000 | $4.3 million | 0.22% | -50,000 |
| Verrica Pharmaceuticals Inc. VRCA | 707,338 | $4.3 million | 0.21% | no change |
| Compass Pathways PLC CMPS | 301,183 | $4.3 million | 0.21% | -807,300 |
| MBX Biosciences Inc. MBX | 75,000 | $4.1 million | 0.21% | -75,000 |
| Research Alliance Corp Iii Ord Shs Cl A RACC | 370,000 | $4.0 million | 0.20% | new |
| Immunovant Inc. IMVT | 100,000 | $3.9 million | 0.19% | no change |
| Amanat Acquisition Corp. AMAN | 375,000 | $3.8 million | 0.19% | new |
| Biohaven Ltd BHVN | 250,000 | $3.7 million | 0.18% | new |
| Sensei Biotherapeutics Inc. FTH | 144,404 | $3.6 million | 0.18% | new |
| Karyopharm Therapeutics Inc. KPTI | 312,500 | $3.1 million | 0.15% | -187,500 |
| Alector Inc. ALEC | 1,510,000 | $3.0 million | 0.15% | +1,010,000 |
| Spyglass Pharma Inc. SGP | 131,586 | $2.9 million | 0.15% | -118,414 |
| Crinetics Pharmaceuticals in CRNX | 75,000 | $2.8 million | 0.14% | no change |
| Oaktree Acquisition Corp. III | 250,000 | $2.8 million | 0.14% | no change |
| Jatt II Acquisition Corp. JATT | 200,000 | $2.3 million | 0.11% | new |
| Neumora Therapeutics Inc. NMRA | 1,070,651 | $1.8 million | 0.09% | new |
| Amylyx Pharmaceuticals Inc. AMLX | 98,999 | $1.8 million | 0.09% | new |
| Adlai Nortye Ltd ANL | 153,847 | $1.8 million | 0.09% | -10,901 |
| Spruce Biosciences Inc. SPRB | 30,000 | $1.6 million | 0.08% | new |
| Eikon Therapeutics Inc. EIKN | 98,001 | $1.3 million | 0.06% | new |
| Onkure Therapeutics Inc OKUR | 240,963 | $1.1 million | 0.05% | no change |
| Engene Therapeut ENGN | 600,000 | $1.0 million | 0.05% | new |
| X4 Pharmaceuticals Inc. XFOR | 145,000 | $677,150 | 0.03% | no change |
| Boundless Bio Inc. BOLD | 250,000 | $625,000 | 0.03% | new |
| Lenz Therapeutics Inc. LENZ | 100,000 | $568,000 | 0.03% | no change |
| Q32 Bio Inc. QTTB | 27,777 | $353,879 | 0.02% | no change |
| Orchestra Biomed Holdings in OBIO | 33,400 | $144,121 | 0.01% | -369,150 |
| Nextcure Inc. NXTC | 41,960 | $67,136 | 0.00% | -199,866 |
| Adagio Med Hldgs Inc. ADGM | 80,000 | $52,128 | 0.00% | no change |
| Rocket Pharmaceuticals Inc. RCKTW | 75,000 | $278 | 0.00% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read more
Change is shares against its 13F for the quarter before; the 9 it sold out of are in the box above.Options it reported
| Company | Option | Shares under the options | Value of those shares |
|---|---|---|---|
| Moderna, Inc. MRNA | Puts | 500,000 | $35.0 million |
| Moderna, Inc. MRNA | Calls | 475,000 | $33.3 million |
| ARK Investment Management LLC ARKG | Calls | 750,000 | $31.5 million |
| Eli Lilly & Co. LLY | Calls | 20,000 | $24.0 million |
| Omeros Corp. OMER | Puts | 1,411,300 | $13.4 million |
| Alkermes plc. ALKS | Calls | 250,000 | $13.1 million |
| Uniqure NV QURE | Calls | 200,000 | $9.2 million |
| Evommune Inc. EVMN | Puts | 500,100 | $6.6 million |
| Summit Therapeutics Inc. SMMT | Calls | 100,000 | $1.5 million |
9 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.